AFTech Global’s strategy is to identify and invest into high potential agrifood opportunities around the world, in particular South East Asia and China, with it’s large and growing population base. Climate change, growing global population ( 9 billion by 2050 ) and food demand ( 98% increase by 2050 ) , growing demand for “ safe “ food free of chemical inputs, rapid advances in AgTech ( agriculture technology) are all driving changes in farming and it’s distribution and supply chain.
Based on current global trends and analysis, AFTech Global has identified the following agriculture sectors as investment opportunities with high returns and capital growth.
Just as the green revolution of the’70s gave us bigger tractors, more seed varieties and better irrigation, the next giant leap forward in food production will be the sustainable intensification of farming – doing more with less inputs but on a bigger scale and with greater efficiency, using high tech hydroponic farms growing high demand and high value vegetables and fruits such as tomatoes, capsicum, brocolli, cucumber, beans and strawberries supplying wholesale markets and corporate customers ( supermarket chains, restaurants, manufacturers and exporters).
Medicinal cannabis is a legal, high quality medicine that can be prescribed for people by their doctor. It is derived from cannabis plants and can be used to treat the symptoms of certain medical conditions and the side effects of some treatments. There are different medicinal cannabis products available to treat different conditions.
Broadly speaking, medicinal cannabis is prescribed to relieve the symptoms of medical conditions like epilepsy, multiple sclerosis, Parkinsons Disease, or alleviate the side effects of cancer treatments (such as nausea, pain and loss of appetite). It may also be useful in the palliative care context. . Scientific studies are being undertaken across the globe, with more uses for medicinal cannabis discovered each year.
Both production and manufacturing of medicinal cannabis are regulated by government authorities where licenses and permits are required. Leading-edge technologies are required to produce premium medical grade cannabinoid products for domestic and export markets. Automatic aeroponic (soilless) grow technology combined with industry leading grow methods and operations will allow production of a safe, high yield, quality and consistent raw product. Utilisation of supercritical CO2 extraction technology will result in consistent production of high quality pure cannabis oil.
In 2014 Canada introduced the Marijuana for Medical Purposes Regulations (MMPR), which established and authorised the production and manufacture of medical cannabis through federally approved producers. Since regulations were introduced, the number of registered patients has increased by 1,200 per cent (from 15,545 to 201,398).
This growth is not just limited to Canada.
The global medical cannabis market is projected to grow to US$55.8 billion by 2025, according to business consultants at Grandview Research, constituting about one-third of the overall legal cannabis market, projected to be worth US$146.4 billion by the same year.
Worldwide, Canada, Peru, Chile, Britain and 31 of 50 American states are already tapping into the industry – in the US, legal cannabis is providing some states with a tax windfall.
In October 2018, Canada became the second nation in the world – after Uruguay – to fully legalise the recreational use and purchase of cannabis and related products. The Canadian cannabis industry could generate as much as C$6.5 billion (US$4.9 billion) in sales by 2020, according to government projections.
In 2016, the Australian government introduced regulations to establish a licence and permit scheme for the legal production and manufacture of medical cannabis products for both the domestic and export markets.
This is a global trend, with many countries on the verge of legalising medicinal cannabis, following the lead of Canada, USA and Australia. Just recently in South East Asia, the Thai government in December 2018 legislated for the first time allowing the use of medicinal cannabis.
The timing is right to capitilise on this booming industry through the use of innovative technologies and proven processes to produce a high quality product at a low production cost for both domestic and export markets.